Cargando…

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?

The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective drugs with various mechanisms of action, including nintedanib, ramucirumab, nivolumab, pemb...

Descripción completa

Detalles Bibliográficos
Autor principal:	Morabito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815183/ https://www.ncbi.nlm.nih.gov/pubmed/29448944 http://dx.doi.org/10.1186/s12916-018-1011-0

Ejemplares similares

Pharmacies: an important source of contraception for some adolescents, but not a panacea for all
por: Gonsalves, Lianne, et al.
Publicado: (2023)

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

Is lactate the new panacea for endothelial dysfunction?
por: Nalos, Marek, et al.
Publicado: (2014)

Hemoglobin A(1c) in Diabetes: Panacea or Pointless?
por: Sacks, David B.
Publicado: (2013)

Isothermic Dialysis-a New Panacea for Intradialytic Hypertension?
por: Ganguli, Anirban
Publicado: (2019)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Panacea or pitfall? The introduction of community health extension workers in Uganda
por: Musoke, David, et al.
Publicado: (2020)

Management of Craniopharyngiomas in the Era of Molecular Oncological Therapies: Not a Panacea
por: Gan, Hoong-Wei
Publicado: (2021)

Commentary: High-intensity focused ultrasound - A panacea in the making?
por: Behera, Geeta, et al.
Publicado: (2022)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

BAT Expansion: A Panacea against Obesity? Lessons from LKB1
por: López, Miguel
Publicado: (2017)

The Panacea
Publicado: (1860)

The Panacea
Publicado: (1876)

Video-assisted laryngoscopic devices: Have we found the panacea for difficult airway yet?
por: Gupta, Anju
Publicado: (2017)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023)

Management of Diabetes Mellitus: Could Simultaneous Targeting of Hyperglycemia and Oxidative Stress Be a Better Panacea?
por: Erejuwa, Omotayo O.
Publicado: (2012)

Commentary: Is 3-dimensional printing the panacea for preoperative surgical planning of complex congenital heart disease?
por: Abdullah, Ibrahim
Publicado: (2020)

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
por: Persinger, Rasheda
Publicado: (2021)

Taxus – The Panacea for Cancer Treatment
por: Manish, Lavhle, et al.
Publicado: (2005)

The Three Panaceas
Publicado: (1863)

Panacea for Trouble
Publicado: (1885)

Commentary: “Belt and suspenders” or panacea: A hybrid approach to the complex problem of postmyocardial infarction ventricular septal defect
por: Bagameri, Gabor, et al.
Publicado: (2020)

Urban areas as hotspots for bees and pollination but not a panacea for all insects
por: Theodorou, Panagiotis, et al.
Publicado: (2020)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
por: Liu, Stephen V., et al.
Publicado: (2023)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

The "One Portal" Panacea
Publicado: (1901)

Calomel as a Panacea
Publicado: (1901)

Is Thymol a Panacea?
por: Banerjee, K. P.
Publicado: (1910)

Alcohol as a Panacea
Publicado: (1896)

The Panacea of Modern Gynecology
Publicado: (1886)

The RADS—Panacea or Pain?
por: Balaji, Ravikanth
Publicado: (2022)

Panacea in a Backpack
por: Venkitachalam, Shruti, et al.
Publicado: (2023)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
por: Ganzinelli, Monica, et al.
Publicado: (2015)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Metformin Intervention—A Panacea for Cancer Treatment?
por: Buczyńska, Angelika, et al.
Publicado: (2022)

Improved understanding of NSCLC immunotherapy response mechanisms from single-cell analysis
por: Bienkowska, Kamila Justyna, et al.
Publicado: (2023)

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
por: Xing, Puyuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_coioikg0i5pa475k724j01igp0